EUVIMEDEUVIMED entdecken
Crossref

In Reply: 2023 Update in ambulatory general internal medicine

Jason T Alexander, Simran K Singh, Sachin D Shah, Brianna Lambert, Jeremy P Smith

Cleveland Clinic Journal of Medicine · 2024

DOI: 10.3949/ccjm.91c.03002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cleveland Clinic Journal of Medicine, 2024. Verfasst von Jason T Alexander und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Chicago, Chicago, IL. Hauptthemen laut MEDLINE: Internal Medicine, Ambulatory Care.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We appreciate Ashley Lim’s close read of our review. Regarding the use of SGLT-2 inhibitors in patients without albuminuria, as we point out, the EMPA-KIDNEY trial[1][1] was the first large randomized trial of SGLT-2 inhibitors to enroll patients with chronic kidney disease without albuminuria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Internal MedicineAmbulatory CareHumans

Autor:innen und Institutionen

  • Department of Medicine, University of Chicago, Chicago, IL.
  • Department of Medicine, Case Western Reserve University, Cleveland, OH.
  • Department of Medicine, University of Wisconsin, Madison, WI.

Zitieren

APA

Alexander, J. T., Singh, S. K., Shah, S. D., Lambert, B., & Smith, J. P. (2024). In Reply: 2023 Update in ambulatory general internal medicine. Cleveland Clinic Journal of Medicine. https://doi.org/10.3949/ccjm.91c.03002

Vancouver

Alexander JT, Singh SK, Shah SD, Lambert B, Smith JP. In Reply: 2023 Update in ambulatory general internal medicine. Cleveland Clinic Journal of Medicine. 2024. doi:10.3949/ccjm.91c.03002

BibTeX
@article{Alexander2024,
  author = {Alexander, Jason T and Singh, Simran K and Shah, Sachin D and Lambert, Brianna and Smith, Jeremy P},
  title = {In Reply: 2023 Update in ambulatory general internal medicine},
  journal = {Cleveland Clinic Journal of Medicine},
  year = {2024},
  doi = {10.3949/ccjm.91c.03002}
}
Kostenlos starten →